Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2025-04-20 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司关于续聘2025年度财务审计机构及内控审计机构的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the reappointment of the company's financial audit and internal control audit firm for the year 2025. It details the auditor's qualifications, independence, audit fees, and the approval process by the board and audit committee. It does not contain actual financial statements or audit reports but rather informs shareholders and the public about the proposed auditor appointment, which will be subject to shareholder approval at the 2024 annual general meeting. The document length is about 3091 characters, relatively short and focused on the announcement of auditor reappointment rather than the audit report itself. Therefore, it fits best under Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or financial statement. However, since it is an announcement of auditor appointment and not the audit report itself, it is more appropriate to classify it as a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. The document is not a report publication announcement (RPA) because it does not mention the publication or attachment of a report. It is not a Management or Board change announcement (MANG) because it concerns auditor appointment, not management changes. Hence, the best classification is Regulatory Filings (RNS).
2025-04-20 Chinese
长春百克生物科技股份公司关于部分募投项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Changchun Baike Biotechnology Co., Ltd. regarding the delay of certain fundraising investment projects, specifically the delay of the '600 million doses of acellular pertussis (three-component) combined vaccine project.' It details the fundraising amount, usage status, reasons for the delay, and the impact on the company. The document includes board and supervisory committee meeting approvals and the sponsor's verification opinion. It is a regulatory announcement about the status and delay of a project funded by previously raised capital. The document length is 3727 characters, which is relatively short and focused on a specific announcement rather than a full financial report or detailed management discussion. It does not contain comprehensive financial statements or detailed financial analysis. It is not an annual or interim report, earnings release, or investor presentation. It is not a certification or legal proceeding report. It is a formal disclosure about the delay of a capital project funded by raised funds, which fits best under Capital/Financing Update (CAP) as it relates to the use and progress of raised capital projects and their timelines. Therefore, the appropriate classification is CAP with high confidence.
2025-04-20 Chinese
长春百克生物科技股份公司董事会审计委员会对会计师事务所2024年度履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a report from the Board Audit Committee on the supervision of the accounting firm for the 2024 fiscal year. It details the audit firm's qualifications, the audit process, communications with the audit firm, and the committee's evaluation of the audit firm's performance. It includes references to the audit report issued by the accounting firm and the audit committee's oversight activities. The document is not the full annual report itself but a standalone report focused on the audit and supervision of the accounting firm. This matches the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and related supervisory information. The document length is 2203 characters, which is relatively short but contains substantive content about the audit process and committee oversight, not merely an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2024
2025-04-20 Chinese
长春百克生物科技股份公司2024年度独立董事述职报告（徐大勇-已离任）
Regulatory Filings
2025-04-20 Chinese
国泰海通证券股份有限公司关于长春百克生物科技股份公司2022年限制性股票激励计划首次授予部分第二个归属期及预留授予部分第一个归属期归属条件未成就并作废部分已授予但尚未归属的限制性股票之独立财务顾问意见
Regulatory Filings
2025-04-20 Chinese
长春百克生物科技股份公司内部控制审计报告
Audit Report / Information Classification · 100% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by a certified public accounting firm and addresses the effectiveness of internal control over financial reporting as of December 31, 2024. The content includes auditor responsibilities, management responsibilities, and an audit opinion on internal control effectiveness. The document is relatively short (1190 characters) and is a standalone audit report focused on internal control, not a full annual report or financial statement. This matches the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and applied accounting principles. Therefore, the correct classification is AR. FY 2024
2025-04-20 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.